Your browser is no longer supported. Please, upgrade your browser.
CELG Celgene Corporation monthly Stock Chart
Celgene Corporation
IndexS&P 500 P/E51.34 EPS (ttm)2.66 Insider Own0.20% Shs Outstand780.24M Perf Week1.37%
Market Cap106.35B Forward P/E15.52 EPS next Y8.78 Insider Trans31.27% Shs Float778.90M Perf Month7.99%
Income2.14B PEG2.48 EPS next Q1.78 Inst Own80.20% Short Float1.41% Perf Quarter10.58%
Sales11.68B P/S9.11 EPS this Y28.10% Inst Trans0.08% Short Ratio2.78 Perf Half Y19.97%
Book/sh9.81 P/B13.90 EPS next Y20.55% ROA7.80% Target Price143.09 Perf Year30.29%
Cash/sh11.36 P/C12.00 EPS next 5Y20.72% ROE33.60% 52W Range96.93 - 136.12 Perf YTD17.76%
Dividend- P/FCF39.75 EPS past 5Y11.80% ROI11.70% 52W High0.14% Beta1.90
Dividend %- Quick Ratio4.20 Sales past 5Y18.30% Gross Margin96.20% 52W Low40.63% ATR2.56
Employees7132 Current Ratio4.40 Sales Q/Q17.90% Oper. Margin24.80% RSI (14)69.62 Volatility1.60% 2.05%
OptionableYes Debt/Eq1.87 EPS Q/Q17.00% Profit Margin18.30% Rel Volume0.98 Prev Close135.00
ShortableYes LT Debt/Eq1.80 EarningsJul 27 BMO Payout0.00% Avg Volume3.95M Price136.31
Recom1.90 SMA202.48% SMA509.58% SMA20014.77% Volume3,856,925 Change0.97%
Jul-11-17Resumed Jefferies Buy
Jun-30-17Downgrade BTIG Research Buy → Neutral
Jun-16-17Upgrade Leerink Partners Mkt Perform → Outperform
Jun-01-17Reiterated Mizuho Buy $130 → $134
May-05-17Downgrade Argus Buy → Hold
Mar-09-17Initiated UBS Buy $140
Nov-09-16Downgrade Standpoint Research Buy → Hold
Nov-08-16Initiated Mizuho Buy $130
Jul-15-16Initiated Stifel Buy $138
Apr-29-16Reiterated Sun Trust Rbsn Humphrey Buy $145 → $147
Feb-25-16Initiated Citigroup Buy $130
Jan-20-16Initiated Credit Suisse Outperform
Jan-14-16Initiated Standpoint Research Buy $130
Jan-08-16Initiated Sun Trust Rbsn Humphrey Buy $145
Jan-07-16Initiated Sun Trust Rbsn Humphrey Buy
Nov-06-15Reiterated UBS Buy $156 → $145
Oct-01-15Upgrade JP Morgan Neutral → Overweight
Sep-09-15Initiated Jefferies Buy
Sep-01-15Initiated Raymond James Strong Buy $160
Jul-24-15Reiterated UBS Buy $142 → $156
Jul-20-17 11:50PM  The Best Stock in New Jersey: Celgene Kiplinger
Jul-19-17 10:54AM  The Zacks Analyst Blog Highlights: Apple, JPMorgan, Celgene, PayPal and Vertex Pharmaceuticals Zacks
09:23AM  3 Big Pharma Companies With the Best Projected Return on Investment Motley Fool
Jul-18-17 06:09PM  Top Stock Reports for Apple, JPMorgan & Celgene Zacks
03:25PM  Nasdaq Leads, Apple Firm; Is This Industry Group Set To Recover? Investor's Business Daily
Jul-17-17 12:55PM  David Rolfe's Wedgewood Partners 2nd Quarter Client Letter
08:23AM  3 Stocks to Buy if the Bull Market Fizzles Motley Fool
06:06AM  These 3 Stocks Have Doubled Investors' Money in 2017 Motley Fool
Jul-16-17 11:42AM  Better Buy: Biogen Inc. vs. Celgene Corporation Motley Fool
Jul-14-17 04:11PM  These Are the Best Growth Stocks Right Now in Biotech
09:43AM  Risk Happens Fast: Doug Kass
09:30AM  The Zacks Analyst Blog Highlights: Merck, Celgene, Gilead Sciences, Seattle Genetics and Vanda Pharmaceuticals Zacks
Jul-13-17 06:03PM  MainStay Mutual Fund Enjoying Big Rally, With Stocks Like Alibaba Investor's Business Daily
02:31PM  5 Drug Stocks Well Poised to Beat Q2 Earnings Estimates Zacks
10:30AM  Amgen's Myeloma Drug Improves Overall Survival in Phase III Zacks
09:40AM  Short Sellers Hike Bets in Major Biotechs 24/7 Wall St.
09:30AM  The Zacks Analyst Blog Highlights: Merck, Eli Lilly, Celgene, Gilead Sciences and Shire Zacks
Jul-12-17 05:08PM  Novartis Grabs Key FDA Panel Approval Of Experimental Cancer Drug Investor's Business Daily
03:31PM  Celgene Price Increases Could Add 3 Cents In EPS This Year
09:39AM  Biotech Stock Roundup: Arena Shoots Up on Study Data, CELG Inks Immuno-Oncology Deal Zacks
Jul-11-17 05:59PM  "Fast Money" final trades: AAL, BAC and more CNBC Videos
05:15PM  3 Top Healthcare Stocks to Buy Today Motley Fool
10:23AM  3 Red-Hot Biotech Stocks That Could Get Even Hotter
07:37AM  How Celgene Stock Performed in 2Q17 Market Realist
07:09AM  Why Celgene Corporation Stock Bolted Higher in June Motley Fool
Jul-10-17 08:21PM  3 Growth Stocks for Buy-and-Hold Investors Motley Fool
04:22PM  These 5 Cancer Drugs Will Be the Biggest Winners 5 Years From Now Motley Fool
11:32AM  [$$] BeiGene Boosted by Celgene Deal
11:31AM  Amgen, Inc. (AMGN) Stock Is the Cure for Ailing Portfolios InvestorPlace
Jul-09-17 09:20PM  What the FDA's Hold on 3 Merck Studies Means for Other Drug Makers
07:28AM  Billions of Dollars on the Line for Celgene With These 3 Small Biotechs Motley Fool
Jul-08-17 11:41AM  Investing in These Stocks Now Could Make You a Millionaire Retiree Motley Fool
07:27AM  Better Buy: Amgen Inc. vs. Celgene Corporation Motley Fool
Jul-07-17 04:42PM  Why Celgene's $413 Million Gamble Helps This Small Biotech More Investor's Business Daily
04:30PM  Allergan, Celgene Offer Solid Biotech Value
01:58PM  Is Amgen Making a Mistake?
01:30PM  Allergan, Celgene Offer Solid Biotech Value
12:00PM  Improving Health for This Pharma ETF Investopedia
Jul-06-17 04:52PM  Celgene (CELG), BeiGene Team Up For PD-1 Inhibitor in China Zacks
04:42PM  Celgene Enters PD1 Market with BeiGene Deal
04:28PM  Why HSN, Herman Miller, and BeiGene Jumped Today Motley Fool
04:19PM  Deal May Help Celgene Rival Dow's Merck, Bristol In Cancer Drugs Investor's Business Daily
02:54PM  Celgene is Tardy to This Cancer-Drug Party Bloomberg
02:07PM  Here's Why BeiGene Ltd. Rose as Much as 31.4% on Thursday Motley Fool
12:21PM  Celgene signs deal with BeiGene for tumor cancer treatment Reuters
09:29AM  Biotech Movers: Immuno-Oncology Pact With Celgene Sends BeiGene Shares Soaring
08:35AM  How Transformative Is This Licensing Deal for BeiGene? 24/7 Wall St.
08:27AM  BeiGene stock surges 12% on Celgene cancer collaboration MarketWatch
Jul-05-17 10:31PM  How a Conference Caused Bluebird Bio's Shares to Rocket 33% in June Motley Fool
10:05PM  Celgene to buy BeiGene stake, to develop tumor cancer treatment Reuters
09:00PM  Celgene Corporation Enters Into Global Strategic Immuno-Oncology Collaboration with BeiGene to Advance PD-1 Inhibitor Program for Solid Tumor Cancers Business Wire
05:39PM  FDA puts hold on Merck multiple myeloma trials after deaths Reuters
04:12PM  These 6 Biotech, Drug Plays Are In Buy Range: Investing Action Plan Investor's Business Daily
01:54PM  Bright spots in biotech CNBC Videos
01:26PM  Celgene Stock Will Continue to Rise on MS Drug's Success: Leerink
11:50AM  Celgene: What's in the Pipeline?
09:54AM  These 6 Biotech, Drug Plays Are In Buy Range: Investing Action Plan Investor's Business Daily
09:00AM  Why Gilead Stock Is Back in the Game Investopedia
07:30AM  Celgene Corporation to Announce Second Quarter 2017 Results on July 27, 2017 Business Wire
Jul-02-17 11:01AM  3 Charts That Show Why to Buy Gilead Sciences Stock Now Motley Fool
Jul-01-17 12:02PM  3 Value Stocks for the 2nd Quarter Motley Fool
01:17AM  [$$] Celgene Could Rally Another 20% on Drug Gains
Jun-30-17 09:00PM  Beauty of Weakness; Uncertainty Remains: Rev Shark's Best Blog
04:16PM  Can Celgene, Bluebird Keep Their Lead As Rivals Champ At The Bit? Investor's Business Daily
02:23PM  This Analyst Is Disappointed With Performance Of Celgene's Mongersen, Ozanimod Benzinga
01:10PM  The Cure For Cancer? Look At Your Blood Investor's Business Daily
10:40AM  Bluebird Bio: Too Much Good News?
09:25AM  Can Regeneron Hit $540?
06:00AM  The 9 Best-Selling Prescription Drugs in 2016 (Each One Topped $6 Billion) Motley Fool
04:39AM  Celgene Falls On Downgrade, But Here Are Signs Of Orderly Pullback Investor's Business Daily
Jun-29-17 02:25PM  Celgene, Gilead and Other Red-Hot Biotech Stocks Just Got Run Over
02:00PM  Technology Stocks Smashed as Biotech Soars Investopedia
11:19AM  Which Companies Are Now Outperforming 95% Of All Stocks? Investor's Business Daily
06:46AM  6 Top Stocks You Can Buy and Hold for the Next Decade Motley Fool
Jun-28-17 03:44PM  2 Fastest Growing Biotech Stocks Motley Fool
02:30PM  Apple, Biotechs Lead Nasdaq Rebound; 5 More Leaders Are Showing Resilience Investor's Business Daily
12:39PM  Where to find value in health-care stocks ahead of Senate... CNBC Videos
Jun-27-17 08:50AM  Major Biotech Short Interest Surges 24/7 Wall St.
Jun-26-17 04:17PM  Biotech Stock With 497% Growth, Positive Trial Results Nears Buy Zone Investor's Business Daily
02:52PM  Seattle Genetics: A Disappointing StudyOr Was It?
11:05AM  Agio Pharma Sinks on Midstage Trial 24/7 Wall St.
08:43AM  Corcept Therapeutics Incorporated in 3 Charts Motley Fool
Jun-25-17 11:01AM  3 Reasons to Buy Celgene Stock and Never Sell Motley Fool
Jun-24-17 08:33AM  2 Top Biotech Stocks to Buy on Sale Motley Fool
Jun-23-17 04:36PM  Week In Review: Biotechs, Software Drive Nasdaq; Boeing Tops Airbus; Oil Hit Investor's Business Daily
08:04AM  3 Biotech Stocks for Enterprising Investors Motley Fool
Jun-22-17 04:50PM  Biotech Resurgence Has Bite But No FAANGs Forbes
04:30PM  This Top Biotech Stock Remains Just Within Buy Range Investor's Business Daily
04:27PM  After Celgene, Regeneron Breakouts, This Biotech Stock May Be Next Investor's Business Daily
04:05PM  Why The Biotech Rally Could Still Tack On Another 15% Upside Investor's Business Daily
02:47PM  Which Stocks Are Showing Rising Relative Strength? Investor's Business Daily
12:11PM  Stock Indexes Grip Small Gains, But This New Leader Swings Higher Investor's Business Daily
09:06AM  Otezla Could Significantly Drive Celgenes Revenue Growth Market Realist
09:00AM  Celebrated Photographer Martin Schoeller Shines a Light on People With Psoriatic Disease Including Olympic Swimmer and Author Dara Torres as Part of Celgenes SHOW MORE OF YOU Campaign Business Wire
07:36AM  What Analysts Recommend for Celgene in 2017 Market Realist
06:48AM  Futures: These 2 Big Breakouts Highlight New Market Leadership Investor's Business Daily
Jun-21-17 08:21PM  Celgene Is Headed Much Higher Even After a Monster Breakout +5.24%
06:00PM  Cramer finds where the real growth is in a split market CNBC Videos
05:48PM  Finding real growth in a split market CNBC Videos
05:08PM  Technician: Forget tech, keep buying health-care stocks CNBC Videos
Celgene Corporation discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis, psoriasis, and ankylosing spondylitis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers. The company's products also include VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and acute myeloid leukemia (AML); THALOMID to treat patients with multiple myeloma and erythema nodosum leprosum; and RITALIN and FOCALIN XR products. Its clinical stage products comprise OTEZLA for use in treating various immune-inflammatory diseases; luspatercept for beta-thalassemia and MDS; CC-486 to treat MDS, AML, and solid tumors; AG-881 for glioma with IDH mutations; LSD1 inhibitor to treat non-hodgkin lymphoma and solid tumors; CC-122 and CC-220 to treat hematological and solid tumor cancers, and inflammation and immunology diseases; and durvalumab, an anti-PDL-1 antibody, for multiple hematological cancers. The company has a strategic collaboration with BeiGene, Ltd. It also has collaborative agreements with Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; Sutro Biopharma, Inc.; bluebird bio, Inc.; FORMA Therapeutics Holdings, LLC; OncoMed Pharmaceuticals, Inc.; NantBioScience, Inc.; AstraZeneca PLC; Lycera Corp.; Juno Therapeutics, Inc.; Nurix Inc.; Jounce Therapeutics, Inc.; and Dragonfly Therapeutics, Inc. Celgene Corporation was founded in 1980 and is headquartered in Summit, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MARIO ERNESTDirectorJul 01Option Exercise0.00734087,930Jul 05 07:33 PM
LOUGHLIN JAMES JDirectorJul 01Option Exercise0.00734024,361Jul 05 07:33 PM
Friedman Michael ADirectorJul 01Option Exercise0.0073400Jul 05 07:31 PM
KAPLAN GILLADirectorJul 01Option Exercise0.00734083,801Jul 05 07:32 PM
CASEY MICHAEL DDirectorJul 01Option Exercise0.0073400Jul 05 07:30 PM
COX CARRIE SMITHDirectorJul 01Option Exercise0.00734023,880Jul 05 07:31 PM
BARKER RICHARD WDirectorJul 01Option Exercise0.00734012,066Jul 05 07:29 PM
LOUGHLIN JAMES JDirectorJun 26Option Exercise29.4318,500544,36332,877Jun 27 04:39 PM
LOUGHLIN JAMES JDirectorJun 26Sale133.5718,5002,471,04523,627Jun 27 04:39 PM
HUGIN ROBERT Jsee remarksJun 22Option Exercise29.49178,7205,271,0061,033,909Jun 23 04:02 PM
Friedman Michael ADirectorJun 22Option Exercise59.065,000295,3005,000Jun 23 04:04 PM
Friedman Michael ADirectorJun 22Sale135.005,000675,0000Jun 23 04:04 PM
HUGIN ROBERT Jsee remarksJun 22Sale134.14175,97023,604,616973,909Jun 23 04:02 PM
Friedman Michael ADirectorJun 21Option Exercise59.065,000295,3005,000Jun 23 04:04 PM
CASEY MICHAEL DDirectorJun 21Option Exercise33.889,250313,3909,250Jun 23 04:05 PM
Friedman Michael ADirectorJun 21Sale130.005,000650,0000Jun 23 04:04 PM
CASEY MICHAEL DDirectorJun 21Sale133.059,2501,230,7130Jun 23 04:05 PM
Friedman Michael ADirectorJun 19Option Exercise59.065,000295,3000Jun 20 04:07 PM
MARIO ERNESTDirectorJun 17Option Exercise0.00333087,196Jun 20 04:09 PM
LOUGHLIN JAMES JDirectorJun 17Option Exercise0.00333023,627Jun 20 04:08 PM
Friedman Michael ADirectorJun 17Option Exercise0.0033300Jun 20 04:07 PM
KAPLAN GILLADirectorJun 17Option Exercise0.00333083,067Jun 20 04:08 PM
CASEY MICHAEL DDirectorJun 17Option Exercise0.0033300Jun 20 04:07 PM
VESSEY RUPERTSee remarksJun 15Option Exercise104.164,007417,3584,785Jun 16 04:11 PM
MARIO ERNESTDirectorJun 15Option Exercise0.00375086,863Jun 16 04:11 PM
KAPLAN GILLADirectorJun 15Option Exercise0.00375082,734Jun 16 04:09 PM
LOUGHLIN JAMES JDirectorJun 15Option Exercise0.00375023,294Jun 16 04:10 PM
Haller Julia ADirectorJun 15Option Exercise0.003750575Jun 16 04:09 PM
Friedman Michael ADirectorJun 15Option Exercise0.0037500Jun 16 04:08 PM
BONNEY MICHAEL WDirectorJun 15Option Exercise0.003750375Jun 16 04:06 PM
CASEY MICHAEL DDirectorJun 15Option Exercise0.0037500Jun 16 04:06 PM
VESSEY RUPERTSee remarksJun 15Sale120.184,785575,0380Jun 16 04:11 PM
KAPLAN GILLADirectorJun 01Option Exercise28.979,250267,92682,359Jun 02 04:11 PM
CASEY MICHAEL DDirectorMay 30Option Exercise28.979,250267,926100,612May 31 04:10 PM
LOUGHLIN JAMES JDirectorMay 01Option Exercise28.969,250267,88032,169May 02 04:20 PM
LOUGHLIN JAMES JDirectorMay 01Sale124.009,2501,147,00022,919May 02 04:20 PM
HUGIN ROBERT Jsee remarksApr 10Option Exercise29.0260,0001,741,200973,909Apr 12 04:24 PM
KAPLAN GILLADirectorMar 30Sale123.8314,0331,737,70673,109Mar 31 05:31 PM
KAPLAN GILLADirectorMar 03Option Exercise25.587,500191,81387,142Mar 07 04:37 PM
VESSEY RUPERTSee remarksMar 01Sale124.424,000497,672778Mar 02 04:04 PM
CASEY MICHAEL DDirectorFeb 27Option Exercise25.587,500191,8507,500Mar 01 04:15 PM
CASEY MICHAEL DDirectorFeb 27Sale121.557,500911,6250Mar 01 04:15 PM
VESSEY RUPERTSee remarksFeb 02Option Exercise0.005,62306,773Feb 06 04:14 PM
Celgene Switzerland LLC10% OwnerFeb 01Buy16.00625,00010,000,0003,456,463Feb 01 04:18 PM
HUGIN ROBERT Jsee remarksJan 05Option Exercise27.4322,708622,767913,909Jan 09 04:11 PM
Smith Scott AndrewSee RemarksDec 23Option Exercise0.006,400039,875Dec 27 04:17 PM
PEHL MICHAEL F.See remarksDec 02Option Exercise0.001,88001,880Dec 06 04:05 PM
Smith Scott AndrewSee RemarksDec 02Option Exercise0.003,750035,419Dec 06 04:05 PM
FOUSE JACQUALYN Asee remarksDec 02Option Exercise0.005,000084,392Dec 06 04:04 PM
Alles Mark JSee RemarksDec 02Option Exercise0.006,5600166,134Dec 06 04:03 PM
VESSEY RUPERTSee remarksNov 22Sale123.182,500307,9501,150Nov 30 04:15 PM
PEHL MICHAEL F.See remarksNov 10Option Exercise68.3920,4241,396,77022,052Nov 15 04:22 PM
PEHL MICHAEL F.See remarksNov 10Sale121.0422,0522,669,1490Nov 15 04:22 PM
Friedman Michael ADirectorNov 09Option Exercise31.8018,600591,48018,600Nov 10 04:14 PM
Friedman Michael ADirectorNov 09Sale116.1018,6002,159,4600Nov 10 04:14 PM
HUGIN ROBERT Jsee remarksNov 09Sale120.00100,00012,000,000922,201Nov 14 05:47 PM
CELGENE CORP /DE/10% OwnerOct 24Buy14.00800,15011,202,1004,834,980Oct 26 04:15 PM
CASEY MICHAEL DDirectorOct 18Option Exercise100.067,500750,45092,985Oct 19 04:16 PM
Friedman Michael ADirectorOct 03Option Exercise29.8656,1161,675,36456,116Oct 05 04:09 PM
Friedman Michael ADirectorOct 03Sale103.6656,1165,816,9850Oct 05 04:09 PM
BARKER RICHARD WDirectorSep 23Option Exercise36.9220,000738,40031,332Sep 26 04:08 PM
BARKER RICHARD WDirectorSep 23Sale110.8220,0002,216,40011,332Sep 26 04:08 PM
MARIO ERNESTDirectorSep 23Sale109.4215,0001,641,30090,058Sep 26 04:08 PM
KAPLAN GILLADirectorSep 19Option Exercise29.267,500219,45079,642Sep 20 04:42 PM
KAPLAN GILLADirectorSep 15Sale106.449,7101,033,53272,142Sep 16 04:15 PM
LOUGHLIN JAMES JDirectorAug 23Option Exercise26.3627,500724,85050,419Aug 24 04:28 PM
LOUGHLIN JAMES JDirectorAug 23Sale114.1027,5003,137,75022,919Aug 24 04:28 PM
CASEY MICHAEL DDirectorAug 22Sale114.0143,1344,917,70785,485Aug 23 04:29 PM
HUGIN ROBERT Jsee remarksJul 28Sale110.00100,00011,000,0001,022,201Aug 01 05:04 PM